Amanote Research
Register
Sign In
Phase 1 Trial of the Antiangiogenic Peptide ATN-161 (Ac-PHSCN-Nh2), a Beta Integrin Antagonist, in Patients With Solid Tumours
British Journal of Cancer
- United Kingdom
doi 10.1038/sj.bjc.6603171
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
May 16, 2006
Authors
M E Cianfrocca
K A Kimmel
J Gallo
T Cardoso
M M Brown
G Hudes
N Lewis
L Weiner
G N Lam
S C Brown
D E Shaw
A P Mazar
R B Cohen
Publisher
Springer Science and Business Media LLC
Related search
Correction: A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients With Advanced Cancer
Clinical Cancer Research
Cancer Research
Oncology
A Phase I Study of the HDM2 Antagonist SAR405838 Combined With the MEK Inhibitor Pimasertib in Patients With Advanced Solid Tumours
British Journal of Cancer
Cancer Research
Oncology
Trial of an Aromatic Retinoid in Patients With Solid Tumours
British Journal of Cancer
Cancer Research
Oncology
A Phase I Trial of Ispinesib, a Kinesin Spindle Protein Inhibitor, With Docetaxel in Patients With Advanced Solid Tumours
British Journal of Cancer
Cancer Research
Oncology
Clinical Trial With a Beta-Receptor Antagonist (Propranolol) in Parkinsonism.
Journal of Neurology, Neurosurgery and Psychiatry
Psychiatry
Mental Health
Neurology
Surgery
Phase I Study of TAS-102 Treatment in Japanese Patients With Advanced Solid Tumours
British Journal of Cancer
Cancer Research
Oncology
A Phase I Study of E7080, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Tumours
British Journal of Cancer
Cancer Research
Oncology
Phase 1 Study of the MDM2 Antagonist RO6839921 in Patients With Acute Myeloid Leukemia
Investigational New Drugs
Oncology
Pharmacology
Targeting Hypoxia-Inducible Factor-1α (HIF-1α) in Combination With Antiangiogenic Therapy: A Phase I Trial of Bortezomib Plus Bevacizumab
Oncotarget
Oncology
